Peregrine Pharmaceuticals reported $206.92M in Current Assets for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
AstraZeneca AZN:LN 26.24B 447M
Celldex Therapeutics CLDX:US $ 390.7M 20.14M
Immunogen IMGN:US $ 456.72M 22.03M
Intrexon XON:US $ 153.09M 3.59M
Minerva Neurosciences NERV:US $ 55.7M 6.5M
Newlink Genetics NLNK:US 92.64M 7.03M
Novartis NOVN:VX 45.72B 19.46B
Peregrine Pharmaceuticals PPHM:US $ 206.92M 6.14M
Xencor XNCR:US $ 505.97M 81.6M